AR043822A1 - Formas de dosificacion y procedimientos de tratamiento que usan inhibidores del vegfr - Google Patents

Formas de dosificacion y procedimientos de tratamiento que usan inhibidores del vegfr

Info

Publication number
AR043822A1
AR043822A1 ARP040101102A ARP040101102A AR043822A1 AR 043822 A1 AR043822 A1 AR 043822A1 AR P040101102 A ARP040101102 A AR P040101102A AR P040101102 A ARP040101102 A AR P040101102A AR 043822 A1 AR043822 A1 AR 043822A1
Authority
AR
Argentina
Prior art keywords
dosage forms
mammal
compound
formula
treatment procedures
Prior art date
Application number
ARP040101102A
Other languages
English (en)
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of AR043822A1 publication Critical patent/AR043822A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Procedimientos de tratamiento del crecimiento celular anormal, tal como cánceres, mediante la administración de formas de dosificación de un compuesto de fórmula (1) a un mamífero. Reivindicación 1: Una forma de dosificación para administración a un mamífero, comprendiendo la forma de dosificación un compuesto de fórmula (1): una sal o solvato farmacéuticamente aceptable del mismo, o una mezcla de los mismos, en una cantidad efectiva para proporcionar un valor en plasma sanguíneo AUC a las 24 horas de 25 a 4500 ng.hr/ml del compuesto de fórmula (1=) o metabolitos activos del mismo, tras la administración al mamífero.
ARP040101102A 2003-04-03 2004-04-01 Formas de dosificacion y procedimientos de tratamiento que usan inhibidores del vegfr AR043822A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46069503P 2003-04-03 2003-04-03
US49177103P 2003-07-31 2003-07-31

Publications (1)

Publication Number Publication Date
AR043822A1 true AR043822A1 (es) 2005-08-17

Family

ID=33135143

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040101102A AR043822A1 (es) 2003-04-03 2004-04-01 Formas de dosificacion y procedimientos de tratamiento que usan inhibidores del vegfr

Country Status (16)

Country Link
US (1) US20040224988A1 (es)
EP (1) EP1613320A1 (es)
JP (1) JP2006522087A (es)
KR (1) KR20050119671A (es)
AR (1) AR043822A1 (es)
AU (1) AU2004226586B2 (es)
BR (1) BRPI0409230A (es)
CA (1) CA2520932A1 (es)
MX (1) MXPA05009303A (es)
NL (1) NL1025873C2 (es)
NO (1) NO20055143L (es)
PA (1) PA8599701A1 (es)
RU (2) RU2341263C2 (es)
TW (1) TW200423933A (es)
UY (1) UY28255A1 (es)
WO (1) WO2004087152A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1740184A1 (en) * 2004-03-30 2007-01-10 Pfizer Products Incorporated Combinations of signal transduction inhibitors
CN101052633A (zh) * 2004-11-02 2007-10-10 辉瑞大药厂 制备吲唑化合物的方法
BRPI0518203A2 (pt) * 2004-11-02 2009-03-10 Pfizer mÉtodos para preparaÇço de compostos indazol
PT1866339E (pt) 2005-03-25 2013-09-03 Gitr Inc Moléculas de ligação a gitr e suas utilizações
JP5528807B2 (ja) 2006-10-12 2014-06-25 アステックス、セラピューティックス、リミテッド 複合薬剤
JP5528806B2 (ja) 2006-10-12 2014-06-25 アステックス、セラピューティックス、リミテッド 複合薬剤
AU2008236444B2 (en) 2007-04-05 2012-06-28 Pfizer Products Inc. Crystalline forms of 6- [2- (methylcarbamoyl) phenylsulfanyl] -3-E- [2- (pyridin-2-yl) ethenyl] indazole suitable for the treatment of abnormal cell growth in mammals
JP5932217B2 (ja) * 2007-07-12 2016-06-08 ジーアイティーアール， インコーポレイテッド Ｇｉｔｒ結合分子を使用する併用療法
SG10201510586PA (en) 2008-06-30 2016-01-28 Mesoblast Inc Treatment of Eye Diseases And Excessive Neovascularization Using A Combined Therapy
BR112014007163A2 (pt) 2011-09-30 2017-04-04 Pfizer composições farmacêuticas de n-metil-2 [3 ((e)-2 piridin-2 il-vinil)-1h-indazol-6 ilsulfanil]-benzamida
AU2012335254A1 (en) 2011-11-11 2014-05-08 Pfizer Inc. N-methyl-2-[3-((E)-2-pyridin-2-yl-vinyl)-1H-indazol-6-ylsulfanyl]-benzamide for the treatment of chronic myelogenous leukemia
EP2792360A1 (en) 2013-04-18 2014-10-22 IP Gesellschaft für Management mbH (1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,2b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide for use in treating HCV
TR201901507T4 (tr) 2014-02-04 2019-02-21 Merck Sharp & Dohme Kanseri tedavi etmeye yönelik bir pd-1 antagonsitinin ve bir vegfr inhibitörünün kombinasyonu.
JP6414727B2 (ja) * 2014-04-01 2018-10-31 公益財団法人ヒューマンサイエンス振興財団 関節疾患の治療予防剤
CN104013589A (zh) * 2014-05-07 2014-09-03 万特制药(海南)有限公司 一种阿西替尼口腔崩解片及其制备方法
US10695426B2 (en) 2014-08-25 2020-06-30 Pfizer Inc. Combination of a PD-1 antagonist and an ALK inhibitor for treating cancer
CN107405401B (zh) 2015-02-26 2022-02-01 默克专利股份公司 用于治疗癌症的pd-1/pd-l1抑制剂
KR20180018762A (ko) 2015-06-16 2018-02-21 메르크 파텐트 게엠베하 Pd-l1 길항제 조합 치료
AU2017217677A1 (en) 2016-02-08 2018-07-26 Vitrisa Therapeutics, Inc. Compositions with improved intravitreal half-life and uses thereof
BR112019006504A2 (pt) 2016-10-06 2019-06-25 Merck Patent Gmbh regime de dosagem de avelumabe para o tratamento de câncer
WO2020128893A1 (en) 2018-12-21 2020-06-25 Pfizer Inc. Combination treatments of cancer comprising a tlr agonist
WO2023166420A1 (en) 2022-03-03 2023-09-07 Pfizer Inc. Multispecific antibodies and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5587458A (en) * 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
CA2129663C (en) * 1992-02-06 2005-07-05 James S. Huston Biosynthetic binding protein for cancer marker
US5339184A (en) * 1992-06-15 1994-08-16 Gte Laboratories Incorporated Fiber optic antenna remoting for multi-sector cell sites
US5459607A (en) * 1993-04-19 1995-10-17 C-Cor/Comlux, Inc. Synchronous optical digital transmission system and method
US5863949A (en) * 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
DK0821671T3 (da) * 1995-04-20 2001-04-23 Pfizer Arylsulfonylhydroxamsyrederivater som MMP- og TNF-inhibitorer
US5747498A (en) * 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US5880141A (en) * 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
JP3588984B2 (ja) * 1997-08-20 2004-11-17 Ｋｄｄｉ株式会社 光パワー計測システム並びにそのための端局及び中継器
GB2332603B (en) * 1997-12-22 2000-07-19 Lsi Logic Corp Improvements relating to multidirectional communication systems
US6529303B1 (en) * 1998-03-05 2003-03-04 Kestrel Solutions, Inc. Optical communications networks utilizing frequency division multiplexing
TWI262914B (en) * 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
PE20010306A1 (es) * 1999-07-02 2001-03-29 Agouron Pharma Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
US6643470B1 (en) * 1999-10-01 2003-11-04 Matsushita Electric Industrial Co., Ltd. FM signal converter, FM signal optical transmitter and FM signal optical receiver

Also Published As

Publication number Publication date
NL1025873A1 (nl) 2004-10-05
US20040224988A1 (en) 2004-11-11
BRPI0409230A (pt) 2006-03-28
AU2004226586A1 (en) 2004-10-14
KR20050119671A (ko) 2005-12-21
NO20055143D0 (no) 2005-11-02
RU2341263C2 (ru) 2008-12-20
NL1025873C2 (nl) 2006-02-14
WO2004087152A1 (en) 2004-10-14
CA2520932A1 (en) 2004-10-14
RU2005128791A (ru) 2006-05-10
RU2008122358A (ru) 2009-12-10
EP1613320A1 (en) 2006-01-11
MXPA05009303A (es) 2005-10-05
NO20055143L (no) 2006-01-03
TW200423933A (en) 2004-11-16
JP2006522087A (ja) 2006-09-28
PA8599701A1 (es) 2004-11-26
AU2004226586B2 (en) 2008-12-11
UY28255A1 (es) 2004-11-30

Similar Documents

Publication Publication Date Title
AR043822A1 (es) Formas de dosificacion y procedimientos de tratamiento que usan inhibidores del vegfr
NO20075042L (no) Farmasoytisk sammensetning innbefattende en omega-karboksyarylsubstituert difenylurea for behandling av cancer
ES2566973T3 (es) Uso de SNS-595 para tratar leucemia
ECSP055867A (es) Derivados de pirrolopirimidina
NO20061506L (no) Heterocykliske inhibitorer av MEK og fremgangsmater for anvendelse derav
ECSP099436A (es) Acilaminopirazoles como inhibidores de fgfr
AR059948A1 (es) Formas farmaceuticas y metodos de tratamiento que usan un inhibidor de la tirosinacinasa
PT1487461E (pt) Métodos de utilização e composições compreendendo compostos imunomoduladores para o tratamento e gestão de síndromes mielodisplásicas
AR090143A2 (es) Composicion farmaceutica para inhibir el crecimiento de celulas anormales
MXPA05004778A (es) Metodos de uso y composiciones que contienen compuestos inmunomoduladores para el tratamiento y manejo de enfermedades mieloproliferativas.
UY29087A1 (es) Derivados de adamantilo, composiciones farmaceuticas que los contienen, procesos para su preparacion y uso terapeutico
CO6390066A2 (es) Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas
NO20060981L (no) Pyridazinderivater og deres anvendelse som terapeutiske midler
AR100772A1 (es) Métodos para aumentar la inhibición tónica y tratar el insomnio secundario
ECSP056194A (es) Derivados de pirazolo-quinazolina, procedimiento para su preparacion y su uso como inhibidores de quinasa
UY29085A1 (es) Derivados de pirimidina 4-sulfonamido sustituidos, compuestos intermedios para su preparación, procedimientos de preparación, composiciones medicinales conteniéndolos y aplicaci0nes
NO20060974L (no) Pyridazinderivater og deres anvendelse som terapeutiske midler
BRPI0511512A (pt) derivados pirrolpirimidina úteis no tratamento do cáncer
CO6331425A2 (es) Composiciones que comprenden n-(3,4-difluoro-2-(2-fluoro-4-yodofenilamino)6-metoxifenil)-1-(2,3-dihidroxiproxipropil)ciclopropan-1-sulfamida
HN2004000232A (es) " derivados de pirrolo(3,4-c) pirazol activos como inhibidores de quinasa, proceso para su preparacion y composiciones farmaceuticas que los comprenden."
GB0112348D0 (en) Compounds
UY28979A1 (es) Derivados de hidrocloruros de 3-carboxamida, composiciones farmacéuticas que los contienen, procedimiento de preparación y su uso, útiles como inhibidores selectivos de gsk3
AU2008284364A1 (en) Use of phosphatases to treat neuroblastomas and medulloblastomas
RU2008145714A (ru) Пуриновые производные в качестве активатора аденозинового рецептора
AR061166A1 (es) Composiciones farmaceuticas para la liberacion sostenida de fenilferina

Legal Events

Date Code Title Description
FA Abandonment or withdrawal